Related Experiment Video

Updated: Jun 2, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Cardioprotective role of statins in chronic kidney disease: do we have the answer?

Bengt C Fellström1

  • 1Department of Nephrology, Uppsala University, Uppsala, Sweden. bengt.fellstrom@medsci.uu.se

Kidney International
|April 15, 2011
PubMed

Insights

Patients with advanced chronic kidney disease (CKD) receive fewer statins post-myocardial infarction, despite proven survival benefits in earlier CKD stages. Increased statin use in CKD classes 1-4 after heart attack is recommended.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Observational study by Szummer et al. investigated statin use in myocardial infarction patients with chronic kidney disease (CKD).
  • Statin therapy is known to improve survival in CKD classes 1-4.
  • Patients with advanced CKD (class 5) were noted to be undertreated with statins post-myocardial infarction.

Discussion:

  • The study highlights a potential disparity in cardiovascular care for CKD patients.
  • Despite study limitations, the findings suggest a need for re-evaluation of treatment protocols.
  • The undertreatment observed may reflect concerns about statin efficacy or safety in advanced CKD, which warrants further investigation.

Key Insights:

  • Patients with chronic kidney disease (CKD) stages 1-4 experience reduced statin prescription rates following myocardial infarction.
  • Statin therapy demonstrates a survival benefit for patients across CKD stages 1-4.
  • The findings suggest that current clinical practice may not fully align with evidence-based recommendations for statin use in post-myocardial infarction CKD patients.

Outlook:

  • Further research is needed to understand the reasons behind the observed undertreatment of statins in advanced CKD patients post-myocardial infarction.
  • Clinical guidelines may need revision to ensure optimal statin utilization in this patient population.
  • The results align with findings from the Study of Heart and Renal Protection (SHARP), reinforcing the importance of statins in CKD management.

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...